<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">cardiotomsk</journal-id><journal-title-group><journal-title xml:lang="ru">Сибирский журнал клинической и экспериментальной медицины</journal-title><trans-title-group xml:lang="en"><trans-title>Siberian Journal of Clinical and Experimental Medicine</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2713-2927</issn><issn pub-type="epub">2713-265X</issn><publisher><publisher-name>TSU publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.29001/2073-8552-2022-778</article-id><article-id custom-type="elpub" pub-id-type="custom">cardiotomsk-2397</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Статьи</subject></subj-group></article-categories><title-group><article-title>Клинико-лабораторные факторы, определявшие прогноз пациентов с COVID-19 в Республике Мордовия: рестроспективное одноцентровое исследование</article-title><trans-title-group xml:lang="en"><trans-title>Clinical and laboratory factors determining negative outcomes of inpatients with COVID-19 in the Republic of Mordovia: a retrospective single-center study</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2290-0013</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Балыкова</surname><given-names>Л. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Balykova</surname><given-names>L. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Балыкова Лариса Александровна, д-р мед. наук, профессор, чл.-корр. РАН, проректор по инновационной деятельности в сфере биотехнологии и медицины, профессор кафедры педиатрии</p><p>430005, Республика Мордовия, Саранск, ул. Большевистская, 68</p></bio><bio xml:lang="en"><p>Larisa A. Balykova, Dr. Sci. (Med.), Professor, Corresponding Member of RAS, Vice-rector for Innovation in the Field of Biotechnology and Medicine; Professor, Department of Dediatrics</p><p>68, Bolshevistskaya str., Saransk, 430005, Republic of Mordovia</p></bio><email xlink:type="simple">larisabalykova@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1383-2474</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Радаева</surname><given-names>О. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Radaeva</surname><given-names>O. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Радаева Ольга Александровна, д-р мед. наук, профессор, заведующий кафедрой иммунологии, микробиологии и вирусологии с курсом клинической иммунологии и аллергологии</p><p>430005, Республика Мордовия, Саранск, ул. Большевистская, 68</p></bio><bio xml:lang="en"><p>Olga A. Radaeva, Dr. Sci. (Med.), Professor, Head of the Department of Immunology, Microbiology and Virology with a Course of Clinical Immunology and Allergology</p><p>68, Bolshevistskaya str., Saransk, 430005, Republic of Mordovia</p></bio><email xlink:type="simple">radaevamed@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8373-6109</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Козлов</surname><given-names>Е. Д.</given-names></name><name name-style="western" xml:lang="en"><surname>Kozlov</surname><given-names>E. D.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Козлов Евгений Дмитриевич, старший преподаватель, кафедра амбулаторно-поликлинической терапии</p><p>430005, Республика Мордовия, Саранск, ул. Большевистская, 68</p></bio><bio xml:lang="en"><p>Evgeniy D. Kozlov, Senior Lecturer, Department of Outpatient Therapy</p><p>68, Bolshevistskaya str., Saransk, 430005, Republic of Mordovia</p></bio><email xlink:type="simple">dr.kozlov@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0001-7347-9679</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Поршина</surname><given-names>В. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Porshina</surname><given-names>V. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Поршина Вероника Александровна, студент</p><p>430005, Республика Мордовия, Саранск, ул. Большевистская, 68</p></bio><bio xml:lang="en"><p>Veronika A. Porshina, Student</p><p>68, Bolshevistskaya str., Saransk, 430005, Republic of Mordovia</p></bio><email xlink:type="simple">v.porshina@list.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7358-6327</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Куляпкин</surname><given-names>В. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Kulyapkin</surname><given-names>V. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Куляпкин Владислав Витальевич, соискатель, кафедра иммунологии, микробиологии и вирусологии с курсом клинической иммунологии и аллергологии</p><p>430005, Республика Мордовия, Саранск, ул. Большевистская, 68</p></bio><bio xml:lang="en"><p>Vladislav V. Kulyapkin, Applicant, Department of Immunology, Microbiology and Virology with a Course in Clinical Immunology and Allergology</p><p>68, Bolshevistskaya str., Saransk, 430005, Republic of Mordovia</p></bio><email xlink:type="simple">vladislavkulyapkin@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0115-4218</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Бабушкин</surname><given-names>И. О.</given-names></name><name name-style="western" xml:lang="en"><surname>Babushkin</surname><given-names>I. O.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Бабушкин Илья Олегович, ординатор по специальности «Онкология», лаборант, кафедра иммунологии, микробиологии и вирусологии с курсом клинической иммунологии и аллергологии</p><p>430005, Республика Мордовия, Саранск, ул. Большевистская, 68</p></bio><bio xml:lang="en"><p>Ilya O. Babushkin, Resident in Specialty – Oncology; Technical Assistant, Department of Immunology, Microbiology and Virology with a Course in Clinical Immunology and Allergology</p><p>68, Bolshevistskaya str., Saransk, 430005, Republic of Mordovia</p></bio><email xlink:type="simple">ilbabu1999@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Национальный исследовательский Мордовский государственный университет имени Н.П. Огарёва (МГУ им. Н.П. Огарёва)</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Federal State Budgetary Educational Institution of Higher Education «National Research Ogarev Mordovia State University» (MRSU)</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2022</year></pub-date><pub-date pub-type="epub"><day>11</day><month>09</month><year>2024</year></pub-date><volume>0</volume><issue>0</issue><issue-title>Принято в печать</issue-title><elocation-id>2397</elocation-id><permissions><copyright-statement>Copyright &amp;#x00A9; Балыкова Л.А., Радаева О.А., Козлов Е.Д., Поршина В.А., Куляпкин В.В., Бабушкин И.О., 2022</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="ru">Балыкова Л.А., Радаева О.А., Козлов Е.Д., Поршина В.А., Куляпкин В.В., Бабушкин И.О.</copyright-holder><copyright-holder xml:lang="en">Balykova L.A., Radaeva O.A., Kozlov E.D., Porshina V.A., Kulyapkin V.V., Babushkin I.O.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.sibjcem.ru/jour/article/view/2397">https://www.sibjcem.ru/jour/article/view/2397</self-uri><abstract><p>Пандемия COVID-19, вызванная вирусом SARS-CoV-2, оказала сильное влияние на глобальное здравоохранение и общество и стала одной из самых смертоносных в истории. Знание факторов риска летального исхода критически важно в формировании организационно-методических и клинических решений для ограничения прогрессирования заболевания и снижения числа летальных исходов. Однако до сих пор не ясно, могут ли общепризнанные факторы риска быть одинаково полезны в выявлении групп риска на разнопрофильной популяции пациентов малых городов.</p><sec><title>Цель</title><p>Цель: оценить значимость демографических, клинических и лабораторных характеристик в прогнозировании летального исхода пациентов с COVID-19, проходивших лечение в отделении реанимации и интенсивной терапии (ОРИТ) многопрофильного ковидного госпиталя города Саранска.</p></sec><sec><title>Материал и методы</title><p>Материал и методы. Проведено одноцентровое ретроспективное обсервационное исследование. Проанализированы медицинские карты 153 стационарных пациентов (из них 134 выздоровевших и 19 погибших) с лабораторно подтвержденной новой коронавирусной инфекцией (НКИ), находившихся на лечении в ОРИТ ГБУЗ РМ «РКБ имени С.В. Каткова» в период с 24.03.2020 по 31.12.2020 гг. Демографические, клинико-лабораторные и рентгенологические характеристики, осложнения и терапия сравнивали между умершими и выздоровевшими пациентами. Показатель смертности в стационаре был основной конечной точкой. Факторы риска летального исхода анализировали с помощью модели логистической регрессии.</p></sec><sec><title>Результаты</title><p>Результаты. Многофакторный регрессионный анализ показал, что в исследуемой популяции, включавшей пациентов как терапевтического, так и хирургического профиля, более высокому риску смерти в стационаре были подвержены пациенты, имевшие в анамнезе ишемическую болезнь сердца (ИБС), хронические неспецифические заболевания легких (ХНЗЛ), острую хирургическую патологию, креатинин плазмы при поступлении в ОРИТ больше 106 мкмоль/л. А наличие лихорадки на момент госпитализации имело защитный эффект в отношении внутрибольничной смертности. Мы также выявили, что умершие пациенты при поступлении в ОРИТ имели более низкие показатели сатурации кислорода, чаще получали инвазивную искусственную вентиляцию легких (ИВЛ) и бóльшие дозы дексаметазона в лечении.</p></sec><sec><title>Заключение</title><p>Заключение. В настоящем исследовании установлены предикторы летального исхода у госпитализированных в ОРИТ пациентов с COVID-19 в Республике Мордовия, которые несколько отличаются от таковых в более крупных городах и свидетельствуют о большом вкладе сопутствующих заболеваний в негативный исход. Мы не выявили значимого вклада многих предложенных лабораторных маркеров в прогнозирование летального исхода. Представленные данные могут помочь организаторам и практикующим врачам в оптимизации организационно-методических и клинических подходов к оказанию медицинской помощи пациентам для снижения риска негативного исхода COVID-19.</p></sec></abstract><trans-abstract xml:lang="en"><p>The COVID-19 pandemic, caused by the SARS-CoV-2 virus, had a profound impact on global health, and society and become one of the deadliest in history. Knowledge of risk factors for mortality is critically important in the formation of organizational, methodological and clinical decisions to limit disease progression and reduce the number of fatal outcomes. However, it is still unclear whether generally accepted risk factors can be equally useful in identifying risk groups in a diverse population of patients in small cities.</p><sec><title>Aim</title><p>Aim: To evaluate the utility of demographic, clinical, and laboratory characteristics in the prediction of negative outcome of patients with COVID-19 admitted to the intensive care unit (ICU) of the multidisciplinary COVID-19 hospital in the city of Saransk.</p></sec><sec><title>Material and Methods</title><p>Material and Methods. Medical records of 153 patients (including 134 recovered and 19 dead) with laboratory-confirmed SARS-CoV-2 infection treated in the intensive care unit of the S.V. Katkov Republican Clinical Hospital between March and December of 2020 were included in this retrospective, single-center, clinical trial. Demographic, clinical, and laboratory characteristics, complications and therapeutic interventions were compared between deceased and recovered patients. The primary endpoint was in-hospital all-cause mortality. Risk factors for mortality were analyzed using logistic regression.</p></sec><sec><title>Results</title><p>Results. Multivariate regression analysis showed that in the population studied, included both therapeutic and surgical patients, a history of coronary artery disease, chronic non-specific lung disease, acute surgical conditions, plasma creatinine at ICU admission ≥ 106 µmol/L had a negative effect on in-hospital mortality, whereas fever at admission had a protective effect. Patients who died had lower oxygen saturation upon the admission to ICU and were more likely to receive invasive mechanical ventilation and higher doses of dexamethasone in treatment.</p></sec><sec><title>Conclusion</title><p>Conclusion. The present study identified predictors to mortality of patients with COVID-19, treated in the ICU of a Mordovia Republic hospital (Russia), which were somewhat different from those previously reported for larger cities and indicate a large contribution of concomitant diseases to the negative outcome. We did not identify a significant contribution of many proposed laboratory markers to predicting mortality. These findings may help authorities and clinicians optimize organizational, methodological, and clinical approaches to medical care of patients to reduce the risk of a negative outcome from COVID-19.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>COVID-19</kwd><kwd>интенсивная  терапия</kwd><kwd>факторы  риска</kwd><kwd>негативный прогноз</kwd><kwd>анализ смертности</kwd><kwd>сопутствующая патология</kwd></kwd-group><kwd-group xml:lang="en"><kwd>COVID-19</kwd><kwd>intensive care</kwd><kwd>risk factors</kwd><kwd>negative outcome</kwd><kwd>mortality analysis</kwd><kwd>concomitant diseases</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">COVID-19 Dashboard (2019-nCoV) by the Center for Systems Science and Engineering [Internet]. Johns Hopkins University (JHU). URL: https://gisanddata.maps.arcgis.com/apps/dashboards/bda7594740fd40299423467b48e9ecf6 (15.05.2024).</mixed-citation><mixed-citation xml:lang="en">COVID-19 Dashboard (2019-nCoV) by the Center for Systems Science and Engineering [Internet]. Johns Hopkins University (JHU). URL: https://gisanddata.maps.arcgis.com/apps/dashboards/bda7594740fd40299423467b48e9ecf6 (15.05.2024).</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Kloka J.A., Blum L.V., Old O., Zacharowski K., Friedrichson B. Characteristics and mortality of 561,379 hospitalized COVID-19 patients in Germany until December 2021 based on real-life data. Sci. Rep. 2022;12(1):11116. DOI: 10.1038/s41598-022-15287-3.</mixed-citation><mixed-citation xml:lang="en">Kloka J.A., Blum L.V., Old O., Zacharowski K., Friedrichson B. Characteristics and mortality of 561,379 hospitalized COVID-19 patients in Germany until December 2021 based on real-life data. Sci. Rep. 2022;12(1):11116. DOI: 10.1038/s41598-022-15287-3.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Wu Z., McGoogan J.M. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72 314 cases from the Chinese center for disease control and prevention. JAMA. 2020;323(13):1239–1242. DOI: 10.1001/jama.2020.2648.</mixed-citation><mixed-citation xml:lang="en">Wu Z., McGoogan J.M. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72 314 cases from the Chinese center for disease control and prevention. JAMA. 2020;323(13):1239–1242. DOI: 10.1001/jama.2020.2648.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Shi C., Wang L., Ye J., Gu Z., Wang S., Xia J. et al. Predictors of mortality in patients with coronavirus disease 2019: a systematic review and meta-analysis. BMC Infect. Dis. 2021;21(1):663. DOI: 10.1186/s12879-021-06369-0.</mixed-citation><mixed-citation xml:lang="en">Shi C., Wang L., Ye J., Gu Z., Wang S., Xia J. et al. Predictors of mortality in patients with coronavirus disease 2019: a systematic review and meta-analysis. BMC Infect. Dis. 2021;21(1):663. DOI: 10.1186/s12879-021-06369-0.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Albitar O., Ballouze R., Ooi J.P., Sheikh Ghadzi S.M. Risk factors for mortality among COVID-19 patients. Diabetes Res. Clin. Pract. 2020;166:108293. DOI: 10.1016/j.diabres.2020.108293.</mixed-citation><mixed-citation xml:lang="en">Albitar O., Ballouze R., Ooi J.P., Sheikh Ghadzi S.M. Risk factors for mortality among COVID-19 patients. Diabetes Res. Clin. Pract. 2020;166:108293. DOI: 10.1016/j.diabres.2020.108293.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Dorjee K., Kim H., Bonomo E., Dolma R. Prevalence and predictors of death and severe disease in patients hospitalized due to COVID-19: A comprehensive systematic review and meta-analysis of 77 studies and 38,000 patients. PLoS One. 2020;15(12):e0243191. DOI: 10.1371/journal.pone.0243191.</mixed-citation><mixed-citation xml:lang="en">Dorjee K., Kim H., Bonomo E., Dolma R. Prevalence and predictors of death and severe disease in patients hospitalized due to COVID-19: A comprehensive systematic review and meta-analysis of 77 studies and 38,000 patients. PLoS One. 2020;15(12):e0243191. DOI: 10.1371/journal.pone.0243191.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Gao Y.D., Ding M., Dong X., Zhang J.J., Kursat Azkur A., Azkur D. et al. Risk factors for severe and critically ill COVID-19 patients: A review. Allergy. 2021;76(2):428–455. DOI: 10.1111/all.14657.</mixed-citation><mixed-citation xml:lang="en">Gao Y.D., Ding M., Dong X., Zhang J.J., Kursat Azkur A., Azkur D. et al. Risk factors for severe and critically ill COVID-19 patients: A review. Allergy. 2021;76(2):428–455. DOI: 10.1111/all.14657.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Ali A.M., Rostam H.M., Fatah M.H., Noori C.M., Ali K.M., Tawfeeq H.M. Serum troponin, D-dimer, and CRP level in severe coronavirus (COVID-19) patients. Immun. Inflamm. Dis. 2022;10(3):e582. DOI: 10.1002/iid3.582.</mixed-citation><mixed-citation xml:lang="en">Ali A.M., Rostam H.M., Fatah M.H., Noori C.M., Ali K.M., Tawfeeq H.M. Serum troponin, D-dimer, and CRP level in severe coronavirus (COVID-19) patients. Immun. Inflamm. Dis. 2022;10(3):e582. DOI: 10.1002/iid3.582.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Zhou F., Yu T., Du R., Fan G., Liu Y., Liu Z. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–1062. DOI: 10.1016/S0140-6736(20)30566-3.</mixed-citation><mixed-citation xml:lang="en">Zhou F., Yu T., Du R., Fan G., Liu Y., Liu Z. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–1062. DOI: 10.1016/S0140-6736(20)30566-3.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Smail S.W., Babaei E., Amin K. Hematological, inflammatory, coagulation, and oxidative/antioxidant biomarkers as predictors for severity and mortality in COVID-19: A prospective cohort-study. Int. J. Gen. Med. 2023;16:565–580. DOI: 10.2147/IJGM.S402206.</mixed-citation><mixed-citation xml:lang="en">Smail S.W., Babaei E., Amin K. Hematological, inflammatory, coagulation, and oxidative/antioxidant biomarkers as predictors for severity and mortality in COVID-19: A prospective cohort-study. Int. J. Gen. Med. 2023;16:565–580. DOI: 10.2147/IJGM.S402206.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Временные методические рекомендации «Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Версия 18 (26.10.2023)» (утв. Минздравом России) [Интернет-ресурс]. КонсультантПлюс. URL: https://www.consultant.ru/document/cons_doc_LAW_347896/?ysclid=lw70wb74lv482843922 (15.05.2024).</mixed-citation><mixed-citation xml:lang="en">Temporary guidelines for the prevention, diagnosis, and treatment of the new coronavirus infection COVID-19 (version 18)] [Internet]. Moscow (Russia); Ministry of Health [15.05.2024]. (in Russ.). URL: https://www.consultant.ru/document/cons_doc_LAW_347896/?ysclid=lw70wb74lv482843922</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines [Internet]. National Institutes of Health. URL https://www.covid19treatmentguidelines.nih.gov/ (15.05.2024).</mixed-citation><mixed-citation xml:lang="en">COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines [Internet]. National Institutes of Health. URL https://www.covid19treatmentguidelines.nih.gov/ (15.05.2024).</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Временные методические рекомендации «Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Версия 11 [Internet]. Минздрав России. URL: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/055/735/original/BМР_COVID-19.pdf (15.05.2024).</mixed-citation><mixed-citation xml:lang="en">Temporary guidelines for the prevention, diagnosis, and treatment of the new coronavirus infection COVID-19 (version 11); Moscow (Russia) [Internet]. (In Russ.). URL: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/055/735/original/BМР_COVID-19.pdf (15.05.2024).</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Singer M., Deutschman C.S., Seymour C.W., Shankar-Hari M., Annane D., Bauer M. et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315(8):801–810. DOI: 10.1001/jama.2016.0287.</mixed-citation><mixed-citation xml:lang="en">Singer M., Deutschman C.S., Seymour C.W., Shankar-Hari M., Annane D., Bauer M. et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315(8):801–810. DOI: 10.1001/jama.2016.0287.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Gao Y.D., Ding M., Dong X., Zhang J.J., Kursat Azkur A., Azkur D. et al. Risk factors for severe and critically ill COVID-19 patients: A review. Allergy. 2021;76(2):428–455. DOI: 10.1111/all.14657.</mixed-citation><mixed-citation xml:lang="en">Gao Y.D., Ding M., Dong X., Zhang J.J., Kursat Azkur A., Azkur D. et al. Risk factors for severe and critically ill COVID-19 patients: A review. Allergy. 2021;76(2):428–455. DOI: 10.1111/all.14657.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Cummings M.J., Baldwin M.R., Abrams D., Jacobson S.D., Meyer B.J., Balough E.M. et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. Lancet. 2020;395(10239):1763–1770. DOI: 10.1016/S0140-6736(20)31189-2.</mixed-citation><mixed-citation xml:lang="en">Cummings M.J., Baldwin M.R., Abrams D., Jacobson S.D., Meyer B.J., Balough E.M. et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. Lancet. 2020;395(10239):1763–1770. DOI: 10.1016/S0140-6736(20)31189-2.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">RECOVERY Collaborative Group; Horby P., Lim W.S., Emberson J.R., Mafham M., Bell J.L., Linsell L. et al. Dexamethasone in hospitalized patients with COVID-19. N. Engl. J. Med. 2021;384(8):693–704. DOI: 10.1056/NEJMoa2021436.</mixed-citation><mixed-citation xml:lang="en">RECOVERY Collaborative Group; Horby P., Lim W.S., Emberson J.R., Mafham M., Bell J.L., Linsell L. et al. Dexamethasone in hospitalized patients with COVID-19. N. Engl. J. Med. 2021;384(8):693–704. DOI: 10.1056/NEJMoa2021436.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group; Sterne J.A.C., Murthy S., Diaz J.V., Slutsky A.S., Villar J., Angus D.C. et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: A meta-analysis. JAMA. 2020;324(13):1330–1341. DOI: 10.1001/jama.2020.17023.</mixed-citation><mixed-citation xml:lang="en">WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group; Sterne J.A.C., Murthy S., Diaz J.V., Slutsky A.S., Villar J., Angus D.C. et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: A meta-analysis. JAMA. 2020;324(13):1330–1341. DOI: 10.1001/jama.2020.17023.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Şengül A., Mutlu P., Özdemir Ö., Satıcı C., Turan M.O., Arslan S. et al. Characteristics of our hypoxemic COVID-19 pneumonia patients receiving corticosteroids and mortality-associated factors. Expert Rev. Respir. Med. 2022;16(8):953–958. DOI: 10.1080/17476348.2022.2102480.</mixed-citation><mixed-citation xml:lang="en">Şengül A., Mutlu P., Özdemir Ö., Satıcı C., Turan M.O., Arslan S. et al. Characteristics of our hypoxemic COVID-19 pneumonia patients receiving corticosteroids and mortality-associated factors. Expert Rev. Respir. Med. 2022;16(8):953–958. DOI: 10.1080/17476348.2022.2102480.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Snow T.A.C., Arulkumaran N., Singer M., Choi S.H. Effect of dexamethasone dose on outcomes in acute COVID-19 disease: A systematic review and meta-analysis. J. Infect. 2023;87(6):490–497. DOI: 10.1016/j.jinf.2023.09.008.</mixed-citation><mixed-citation xml:lang="en">Snow T.A.C., Arulkumaran N., Singer M., Choi S.H. Effect of dexamethasone dose on outcomes in acute COVID-19 disease: A systematic review and meta-analysis. J. Infect. 2023;87(6):490–497. DOI: 10.1016/j.jinf.2023.09.008.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
